ICU REACH

ICU REACH Newsletter (December 31, 2025)

December 30, 2025 Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults In this multicenter RCT (n=2,365), critically ill adults undergoing emergency tracheal intubation were randomized to ketamine (n=1176) or etomidate (n=1189) for anesthesia induction. In-hospital mortality by day 28 was 28.1% with...

While ketamine and etomidate demonstrate equivalent outcomes with respect to short-term mortality, their hemodynamic profiles differ meaningfully. Etomidate was associated with greater cardiovascular stability, particularly in high-risk subgroups such as those with sepsis or elevated illness severity

The STORM-PE trial explores the efficacy of mechanical thrombectomy combined with anticoagulation versus anticoagulation alone. Learn more about how these findings could impact treatment approaches in the ICU. 💉💪 Read the full details here: https://wix.to/NXnRqK7

STORM‑PE: First Randomized Trial of Mechanical Thrombectomy + Anticoagulation vs Anticoagulation Alone For intermediate‑high risk PE (with imaging and biomarker evidence of right strain), STORM‑PE shows mechanical thrombectomy can rapidly and safely reduce right heart strain and improve early functional recovery compared with anticoagulation alone.

The latest insights from the TOP trial reveal that while there's no mortality difference between liberal and restrictive transfusion strategies in high cardiac risk postoperative patients, a liberal approach significantly cuts down on cardiac complications. Explore more here: https://wix.to/mLLfUBC

Systemic corticosteroids are recommended for severe CAP based on trials like CAPE-COD and supporting meta-analyses. However, the REMAP-CAP trial found no mortality benefit—and possible harm—from hydrocortisone, raising concerns. Despite this, a Bayesian meta-analysis still supports corticosteroid use in high-risk ICU patients. Clinical decisions should consider disease severity, etiology, and individual patient factors.

Explore the findings of the BALANCE Trial: a pivotal study examining the efficacy of 7 days versus 14 days of antibiotics for bloodstream infections. This research shows that shorter therapy is not only effective but also supports antimicrobial stewardship. Dive deeper here: https://wix.to/HrgwcfF

We uncover the latest findings from the BICARICU-2 trial. Learn how intravenous sodium bicarbonate impacts patients facing severe metabolic acidemia and acute kidney injury. This study illuminates fresh perspectives on renal care. Join the discussion! https://wix.to/sgPHVyz

Buffering Severe Acidemia in AKI: Fresh Data, New Caveats (The BICARICU-2 Trial) In patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not reduce mortality but was associated with a lower rate and delayed initiation of renal replacement therapy.

A groundbreaking study in the NEJM suggests that many patients in shock might not need early arterial catheterization. Could this change standard ICU practices? Check out the full article to share your thoughts! https://wix.to/jTc3nVm

ICU REACH Newsletter (March 9, 2025) https://wix.to/gx1XIbC

ICU REACH Newsletter (December 30, 2024) https://wix.to/39huR5M